WallStreetZenWallStreetZen

NASDAQ: ALGS
Aligos Therapeutics Inc Stock Ownership - Who owns Aligos Therapeutics?

Insider buying vs selling

Have Aligos Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Lawrence BlattChief Executive Officer2023-10-25610,277$0.76
$461.98kBuy
Carole NuechterleinDirector2023-10-257,933,601$0.76
$6.01MBuy
James Paul ScopaDirector2023-10-25183,083$0.76
$138.59kBuy

1 of 1

ALGS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALGS insiders and whales buy or sell their stock.

ALGS Shareholders

What type of owners hold Aligos Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Roche Holding Ltd14.57%11,025,941$10.79MInsider
Carole Nuechterlein14.57%11,025,941$10.79MInsider
Armistice Capital LLC9.03%6,833,875$6.69MInstitution
Ecor1 Capital LLC8.44%6,389,468$6.26MInstitution
Deep Track Capital LP8.07%6,102,770$5.97MInstitution
Vivo Capital LLC4.69%3,547,030$3.47MInstitution
Vivo Capital Viii LLC4.69%3,547,030$3.47MInsider
Versant Venture Capital Vi LP4.35%3,292,339$3.22MInsider
Alyeska Investment Group LP3.81%2,882,216$2.82MInstitution
Altitude Crest Partners Inc3.76%2,844,681$2.78MInstitution

1 of 3

ALGS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALGS54.25%45.75%Net Buying
ANEB24.84%75.16%
PASG43.60%56.40%Net BuyingNet Selling
CKPT13.69%8.02%Net SellingNet Selling
ASMB23.09%76.91%Net BuyingNet Buying

Aligos Therapeutics Stock Ownership FAQ

Who owns Aligos Therapeutics?

Aligos Therapeutics (NASDAQ: ALGS) is owned by 59.93% institutional shareholders, 50.54% Aligos Therapeutics insiders, and 0.00% retail investors. Roche Holding Ltd is the largest individual Aligos Therapeutics shareholder, owning 11.03M shares representing 14.57% of the company. Roche Holding Ltd's Aligos Therapeutics shares are currently valued at $10.81M.

If you're new to stock investing, here's how to buy Aligos Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.